诺和诺德：EVOKEEVOKE + 阿尔茨海默病适应症临床失利-结果不及预期但影响有限

24 November 2025 | 12:15PM GMT Equity Research Novo Nordisk (NOVOb.CO): EVOKE/EVOKE+ miss in Alzheimer's - disappointing but not significantly impactful This morning (November 24th), Novo announced that the EVOKE/EVOKE+ trials of semaglutide in Alzheimer's disease did not hit the primary endpoint, as no efficacy difference was seen between the treatment and placebo arms, leading to the 1-year extension study to be discontinued. Topline results will be presented at the CTAD conference on December 3rd, and No ...